Internal medicine

Low molecular weight heparin

Grading (engineering)

Family medicine

Cancer

Civil engineering

Engineering

Surgery

Intensive care medicine

Clinical Practice

Venous thrombosis

Thrombosis

Venous thromboembolism

Clinical trial

Medicine

The Lancet Oncology

Venous thromboembolism (VTE) is the second leading cause of death in patients with cancer. These patients are at a high risk of VTE recurrence and bleeding during anticoagulant therapy. The International Initiative on Thrombosis and Cancer is an independent academic working group aimed at establishing a global consensus for the treatment and prophylaxis of VTE in patients with cancer. The International Initiative on Thrombosis and Cancer last updated its evidence-based clinical practice guidelines in 2016 with a free, web-based mobile phone application, which was subsequently endorsed by the International Society on Thrombosis and Haemostasis.

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer